Foundation Medicine Drives Awareness on the Importance of Quality and Accuracy in Cancer Biomarker Testing
Quality First initiative features patient advocate stories and educational assets to create awareness on how not all cancer biomarker tests are created equal
Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced today the launch of a new initiative aimed at driving awareness about the importance of high-quality biomarker testing in cancer care. Quality First educates on the role biomarker testing plays in supporting treatment decision-making and how the accuracy and clarity of these tests can impact patients’ being matched to an effective treatment option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716938863/en/
“At Foundation Medicine, we are transforming the future of cancer care through high-quality biomarker tests and services,” said Foundation Medicine Senior Vice President of Corporate Affairs Jennifer Romans. “Cancer is complex, and it requires a personalized, data-driven approach to enable confident care decisions. Not all biomarker tests are created equal and precision cancer care can only be as good as the quality and accuracy of the tests used to inform treatment.”
